PROCW
Procaps Group S.A. WarrantsKey Statistics
About Procaps Group S.A. Warrants
Procaps Group S.A. Warrants (PROCW) offers a compelling investment opportunity in the burgeoning pharmaceutical and health supplements market across Latin America. As a leading integrated healthcare entity, Procaps is distinguished by its innovative delivery technologies and a diverse product portfolio that includes prescription drugs, over-the-counter solutions, and dietary supplements. Underpinned by a strong dedication to research and development, along with an extensive distribution network, Procaps is strategically positioned to meet the rising demand for health and wellness products. With ongoing expansion in both product lines and geographical presence, PROCW warrants careful consideration for institutional investors seeking to capitalize on the robust growth trajectory of the health sector.
Fundamentals
| Revenue (TTM) | $414.10M |
| Gross Profit (TTM) | $227.91M |
| EBITDA | $57.06M |
| Operating Margin | 11.10% |
| Return on Equity | 37.40% |
| Return on Assets | 6.28% |
| Revenue/Share (TTM) | $4.10 |
| Book Value | $0.39 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | -63.70% |
| Quarterly Revenue Growth (YoY) | 7.30% |
| Shares Outstanding | 0 |
| Float | $17.15M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PROCW and any ticker you trade — then tracks every position and per-strategy win rate.